Table 2.
Comparison between baseline categorical variables and serum soluble CD163 levels in patients with polymyositis/dermatomyositis-related interstitial lung disease
| Variables | Soluble CD163, ng/mL | P value |
|---|---|---|
| Male/female | 814 (300–1572)/822 (305–2759) | 0.66 |
| Current or former smoker/never smoker | 791 (300–2758)/834 (305–2512) | 0.39 |
| CADM/others | 730 (305–1750)/862 (300–2759) | 0.09 |
| Fever, yes/no | 1009 (428–2512)/742 (300–2759) | 0.03 |
| Cough, yes/no | 806 (426–1572)/826 (300–2759) | 0.59 |
| Dyspnea, yes/no | 814 (428–2759)/822 (300–1572) | 0.48 |
| Muscle pain or weakness, yes/no | 862 (300–2759)/730 (305–1750) | 0.09 |
| Rash typical of DM, yes/no | 789 (300–2759)/1124 (814–1213) | 0.30 |
| Raynaud’s phenomenon, yes/no | 593 (426–1137)/822 (300–2759) | 0.27 |
| Arthralgia, yes/no | 1124 (305–2512)/773 (300–2759) | 0.02 |
| Anti-MDA5 antibody, positive/negative | 887 (495–2512)/778 (300–2759) | 0.09 |
Data are presented as median (observed range). All P values are derived from the Mann–Whitney U test. CADM clinically amyopathic dermatomyositis, DM dermatomyositis, MDA5 Melanoma differentiation-associated gene 5